Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria

Russo, G.; Ippolito, M.; Cosentino, S.; Murè, G.; Baldari, S.; Sabini, M.; Sardina, D.; Valastro, L.; Bordonaro, R.; Messa, C.; Gilardi, M.; Soto Parra, H.

    Risultato della ricerca: Article

    Abstract

    In this paper the clinical value of PET for early prediction of tumor response to Erlotinib in patients with advanced or metastatic nonsmall cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen is evaluated. The aim was to compare the early metabolic treatment response using European Organization for Research and Treatment of Cancer (EORTC) 1999 recommendations and PET Response Criteria in Solid Tumors (PERCIST), and the standard treatment response using Response Evaluation Criteria in Solid Tumors (RECIST).
    Lingua originaleEnglish
    pagine (da-a)-
    Numero di pagine0
    RivistaTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    Stato di pubblicazionePublished - 2014

    Fingerprint

    Non-Small Cell Lung Carcinoma
    Neoplasms
    Therapeutics
    Drug Therapy
    Research
    Erlotinib Hydrochloride
    Response Evaluation Criteria in Solid Tumors

    Cita questo

    Russo, G.; Ippolito, M.; Cosentino, S.; Murè, G.; Baldari, S.; Sabini, M.; Sardina, D.; Valastro, L.; Bordonaro, R.; Messa, C.; Gilardi, M.; Soto Parra, H. (2014). Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria. THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, -.

    Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria. / Russo, G.; Ippolito, M.; Cosentino, S.; Murè, G.; Baldari, S.; Sabini, M.; Sardina, D.; Valastro, L.; Bordonaro, R.; Messa, C.; Gilardi, M.; Soto Parra, H.

    In: THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, pag. -.

    Risultato della ricerca: Article

    Russo, G.; Ippolito, M.; Cosentino, S.; Murè, G.; Baldari, S.; Sabini, M.; Sardina, D.; Valastro, L.; Bordonaro, R.; Messa, C.; Gilardi, M.; Soto Parra, H. 2014, 'Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria', THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, pagg. -.
    Russo, G.; Ippolito, M.; Cosentino, S.; Murè, G.; Baldari, S.; Sabini, M.; Sardina, D.; Valastro, L.; Bordonaro, R.; Messa, C.; Gilardi, M.; Soto Parra, H. Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria. THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2014;-.
    Russo, G.; Ippolito, M.; Cosentino, S.; Murè, G.; Baldari, S.; Sabini, M.; Sardina, D.; Valastro, L.; Bordonaro, R.; Messa, C.; Gilardi, M.; Soto Parra, H. / Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria. In: THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2014 ; pagg. -.
    @article{d483a8c2ee424dc8be239238105f10cf,
    title = "Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria",
    abstract = "In this paper the clinical value of PET for early prediction of tumor response to Erlotinib in patients with advanced or metastatic nonsmall cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen is evaluated. The aim was to compare the early metabolic treatment response using European Organization for Research and Treatment of Cancer (EORTC) 1999 recommendations and PET Response Criteria in Solid Tumors (PERCIST), and the standard treatment response using Response Evaluation Criteria in Solid Tumors (RECIST).",
    keywords = "RECIST; EORTC; PERCIST; 18F-FDG PET; non–small cell lung cancer",
    author = "{Russo, G.; Ippolito, M.; Cosentino, S.; Mur{\`e}, G.; Baldari, S.; Sabini, M.; Sardina, D.; Valastro, L.; Bordonaro, R.; Messa, C.; Gilardi, M.; Soto Parra, H.} and Alessandro Stefano",
    year = "2014",
    language = "English",
    pages = "--",
    journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",
    issn = "1824-4785",
    publisher = "Edizioni Minerva Medica S.p.A.",

    }

    TY - JOUR

    T1 - Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria

    AU - Russo, G.; Ippolito, M.; Cosentino, S.; Murè, G.; Baldari, S.; Sabini, M.; Sardina, D.; Valastro, L.; Bordonaro, R.; Messa, C.; Gilardi, M.; Soto Parra, H.

    AU - Stefano, Alessandro

    PY - 2014

    Y1 - 2014

    N2 - In this paper the clinical value of PET for early prediction of tumor response to Erlotinib in patients with advanced or metastatic nonsmall cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen is evaluated. The aim was to compare the early metabolic treatment response using European Organization for Research and Treatment of Cancer (EORTC) 1999 recommendations and PET Response Criteria in Solid Tumors (PERCIST), and the standard treatment response using Response Evaluation Criteria in Solid Tumors (RECIST).

    AB - In this paper the clinical value of PET for early prediction of tumor response to Erlotinib in patients with advanced or metastatic nonsmall cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen is evaluated. The aim was to compare the early metabolic treatment response using European Organization for Research and Treatment of Cancer (EORTC) 1999 recommendations and PET Response Criteria in Solid Tumors (PERCIST), and the standard treatment response using Response Evaluation Criteria in Solid Tumors (RECIST).

    KW - RECIST; EORTC; PERCIST; 18F-FDG PET; non–small cell lung cancer

    UR - http://hdl.handle.net/10447/127300

    M3 - Article

    SP - -

    JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

    JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

    SN - 1824-4785

    ER -